Data provided by Nasdaq. Minimum 15 minutes delayed.
December 03, 2018
NantHealth® to Present New Research Findings at the San Antonio Breast Cancer Symposium
Topics to include DNA and RNA profiling and next-generation sequencing of tumors SAN ANTONIO--(BUSINESS WIRE)--Dec. 3, 2018-- Significant developments in breast cancer research will be presented by NantHealth (NASDAQ: NH) at the San Antonio Breast Cancer Symposium this week. NantHealth, a leader in breakthrough cancer research and solutions to improve patient care and lower healthcare costs, will discuss the findings of three investigations, w...
November 15, 2018
NantHealth Reports 2018 Third-Quarter Financial Results
Total Revenue in Q3 was $22.3 Million SaaS revenue of $15.9 million in Q3, up 5% from $15.2 million in prior year Q3 Enhanced efficiencies continued to drive reduced operating expenses and improved adjusted bottom line results Sequencing and Molecular Analysis, 930 total tests ordered in Q3, including 461 GPS Cancer® and 469 Liquid GPS® Tests...
November 07, 2018
NantHealth to Report 2018 Third-Quarter Financial Results and Host Conference Call on Thursday, November 15
--Slight Delay in Reporting Financial Results, Due to Effects of Hurricane Michael-- CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 7, 2018-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 third quarter on Thursday, November 15, 2018, after market close. NantHealth management will host a conference call that same day at 1:30 p....
|There are currently no events scheduled.|